Recent Company News

• 07:08 PM ET Apr 28, 2025
  

  Immutep reports Q3 net cash from / (used in) operating activities (A$16.3M) - Appendix 4C (A$0.26, 0.00)

• 12:53 AM ET Apr 16, 2025
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (34 total)

• 10:18 AM ET Apr 07, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (1167 total)

• 12:55 AM ET Apr 07, 2025
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (196 total)

• 10:10 AM ET Apr 04, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (1064 total)

• 10:11 AM ET Apr 03, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (624 total)

• 05:45 PM ET Mar 24, 2025
  

  Immutep doses first patient in TACTI-004 Phase III trial in first line non-small cell lung cancer (A$0.29, 0.00)

• 07:43 PM ET Mar 19, 2025
  

  Immutep to present TACTI-004 Phase III trial in progress poster at ELCC (A$0.30, -0.01)

• 10:13 AM ET Mar 12, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (110 total)

• 03:04 AM ET Feb 26, 2025
  

  Immutep reports H1 NPAT (A$22.4M) vs year-ago (A$21.2M) (A$0.31, 0.00)